Home / Research library / Survodutide
Survodutide: molecular data, studies & sources
Survodutide is catalogued here as a research compound. This profile brings together the molecular source record, selected indexed publications and available supplier comparisons. Evidence for a named substance does not authenticate a commercial product.
Compiled by PeptideTech Editors · Sources checked · Selected bibliography, not a systematic review
Molecular formula, weight & structure
- Molecular formula (MF)
- C192H289N47O61
- Molecular weight (MW)
- 4232 g/mol
- PubChem compound ID
- 168429725
- Record title
- Survodutide
Values describe the selected PubChem molecular entity. Counterions, salt forms, hydration and sequence changes can alter the supplied material. Confirm the exact identity against the supplier specification.
Source: PubChem CID 168429725 · retrieved 2026-09-21
Chemical identifiers and source data
- IUPAC name
- 18-[[4-[[2-[[(2R)-1-[[2-[[(2R)-1-[[2-[[2-[[(5R)-5-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-5-amino-2-[[1-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]cyclobutanecarbonyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-4-carboxybutanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]amino]propanoyl]amino]hexanoyl]amino]-3-carboxypropanoyl]amino]-3-phenylpropanoyl]amino]-3-methylpentanoyl]amino]-6-[[(2R)-1-[[(2R)-1-[[(2R)-1-[[(2R)-1-[[(2R)-1-amino-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-6-oxohexyl]amino]-2-oxoethyl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-1-carboxy-4-oxobutyl]amino]-18-oxooctadecanoic acid
- InChIKey
- MEDXQFAHWBMVIM-YIUAJOCSSA-N
- SMILES
- CC[C@H](C)[C@@H](C(=O)N[C@H](CCCCNC(=O)CNC(=O)CNC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@@H](CO)NC(=O)CNC(=O)CCC(C(=O)O)NC(=O)CCCCCCCCCCCCCCCCC(=O)O)C(=O)N[C@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCC(=O)O)C(=O)N[C@H](CO)C(=O)N[C@H](C)C(=O)N)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC5=CC=C(C=C5)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC6=CC=CC=C6)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)N)NC(=O)C7(CCC7)NC(=O)[C@H](CC8=CNC=N8)N
Identifiers
- PubChem CID
- 168429725
- ChEMBL ID
- CHEMBL5314776
- InChIKey
- MEDXQFAHWBMVIM-YIUAJOCSSA-N
- Wikidata
- Q123907235
Other names and development codes: BI 456906
Calculated molecular descriptors
| Monoisotopic (exact) mass | 4229.0957 Da |
|---|---|
| Heavy atoms | 300 |
| Hydrogen-bond donors | 62 |
| Hydrogen-bond acceptors | 59 |
| Rotatable bonds | 148 |
| Topological polar surface area | 1761.4 Ų |
| Calculated logP (Crippen) | -15.11 |
| Rings | 8 |
| Stereocenters | 33 |
| Formal charge | 0 |
Computed with RDKit from the published SMILES (Crippen logP, topological polar surface area). Calculated descriptors are not measured properties of a supplied batch.
US regulatory status & drug development
Drugs@FDA lists no NDA, BLA or ANDA with survodutide as an active ingredient (names searched: SURVODUTIDE, BI 456906; checked October 7, 2026). Research-labelled Survodutide listings are not FDA-approved drugs.
An FDA approval covers a defined medicine, formulation and labelled use. It does not extend to research-labelled material sold under the same compound name. Identity basis: Investigational INN; development code BI 456906 also searched.
Source: Drugs@FDA via openFDA (active-ingredient search for SURVODUTIDE, BI 456906) · checked . openFDA data are not intended for clinical decisions.
Drug development record (ChEMBL)
Harmonized drug-development record from ChEMBL. The highest clinical stage is the furthest stage reached, as recorded by ChEMBL; it can lag regulatory approvals, and it is not an approval of a research-supplier product.
- ChEMBL ID
- CHEMBL5314776
- Modality
- Protein / peptide
- Highest clinical stage
- Phase 3
- Record name
- SURVODUTIDE
Mechanism of action
- Glucagon-like peptide 1 receptor agonist · target: Glucagon-like peptide 1 receptor (GLP1R)
- Glucagon receptor agonist · target: Glucagon receptor (GCGR)
Synonyms, codes and trade names
- Synonyms and development codes
- BI 456906 · BI-456906 · BI456906 · Survodutide
Identity check: PubChem / GSRS ChEMBL cross-reference and an exact name match. Source: ChEMBL CHEMBL5314776 (EMBL-EBI, CC BY-SA 3.0) · retrieved 2026-10-07
Registered clinical trials
Studies registered on ClinicalTrials.gov that list Survodutide as an intervention. Studies that only measure the molecule as a biomarker, or use it only as a comparator or background arm for another drug, are excluded. A registration describes a planned or completed protocol; it does not report a result. Active studies are listed first.
27 registered studies matched, 9 currently active or recruiting, 2 with results posted on ClinicalTrials.gov.
- By highest phase
- Phase 3 · 11Phase 2 · 3Phase 1 · 13
- By registry status
- Completed · 18Recruiting · 4Not Yet Recruiting · 3Active Not Recruiting · 2
| Study | Phase · status | Conditions | Sponsor · size |
|---|---|---|---|
| SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose WeightNCT07850050 · start 2026-10-31 · primary completion 2028-07-26 | Phase 3Not Yet Recruiting | Obesity | Boehringer Ingelheim600 participants |
| ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver DiseaseNCT07850063 · start 2026-10-23 · primary completion 2029-04-29 | Phase 3Not Yet Recruiting | Obesity · Metabolic Dysfunction-associated Steatotic Liver Disease | Boehringer Ingelheim600 participants |
| A Study to Compare How 2 Different Formulations of Survodutide Are Taken up in the Body When Given by Injection in Healthy Men and Women With and Without Overweight or ObesityNCT07768813 · start 2026-09-02 · primary completion 2026-12-08 | Phase 1Recruiting | Healthy · Obesity | Boehringer Ingelheim44 participants |
| A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood SugarNCT07754461 · start 2026-08-24 · primary completion 2028-01-17 | Phase 3Recruiting | Type 2 Diabetes | Boehringer Ingelheim600 participants |
| Albuminuria Reduction Study With Survodutide Treatment in Kidney DiseaseNCT07206290 · start 2026-03-02 · primary completion 2027-11-30 | Phase 2Not Yet Recruiting | Chronic Kidney Disease | University Medical Center Groningen120 participants |
| A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With ObesityNCT06745284 · start 2025-03-26 · primary completion 2027-01-08 | Phase 1Active Not Recruiting | Obesity | Boehringer Ingelheim64 participants |
| A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the LiverNCT05202353 · start 2024-11-01 · primary completion 2027-01-06 | Phase 1Active Not Recruiting | Obesity | Boehringer Ingelheim29 participants |
| LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have CirrhosisNCT06632457 · start 2024-11-12 · primary completion 2029-06-05 | Phase 3Recruiting | Metabolic Dysfunction Associated Steatohepatitis | Boehringer Ingelheim1590 participants |
| LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver FibrosisNCT06632444 · start 2024-10-14 · primary completion 2031-12-27 | Phase 3Recruiting | Metabolic Dysfunction Associated Steatohepatitis (MASH) · Liver Fibrosis | Boehringer Ingelheim1800 participants |
| A Study in Healthy People or Otherwise Healthy With Overweight or Obesity to Compare 2 Formulations of Survodutide Given in Different Ways, Either as a Pre-filled Syringe or a Pen-like InjectorNCT07413913 · start 2026-03-03 · primary completion 2026-05-28 | Phase 1Completed | Healthy · Obesity | Boehringer Ingelheim56 participants |
Show 17 more registered studies
Registry check 2026-10-09 · Run this search on ClinicalTrials.gov
Human intervention studies
Selected studies in which participants received Survodutide, with their indexed or reviewed study type. Check the original article for the formulation, population and controls. Studies that only measured the molecule, or used it as a comparator, are listed separately below and are not counted as intervention studies.
- Human study · PubMed trial index Compound given to participants
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.
Sanyal AJ, Bedossa P, Fraessdorf M et al. · The New England journal of medicine · 2024
PMID 38847460 · DOI: 10.1056/NEJMoa2401755 · Registration NCT04771273
- Human study · PubMed trial index Compound given to participants
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial.
le Roux CW, Steen O, Lucas KJ et al. · The lancet. Diabetes & endocrinology · 2024
PMID 38330987 · DOI: 10.1016/S2213-8587(23)00356-X · Registration NCT04667377
- Human study · PubMed trial index Compound given to participants
Survodutide Once Weekly for the Treatment of Adults with Obesity.
le Roux CW, Wharton S, Startseva E et al. · The New England journal of medicine · 2026
PMID 42253238 · DOI: 10.1056/NEJMoa2600751 · Registration NCT06066515
- Human study · PubMed trial index Compound given to participants
Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial.
Blüher M, Rosenstock J, Hoefler J et al. · Diabetologia · 2024
PMID 38095657 · DOI: 10.1007/s00125-023-06053-9
- Human study · PubMed trial index Compound given to participants
Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis.
Lawitz EJ, Fraessdorf M, Neff GW et al. · Journal of hepatology · 2024
PMID 38857788 · DOI: 10.1016/j.jhep.2024.06.003 · Registration NCT05296733
- Human study · PubMed trial index Compound given to participants
Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial.
Kaplan LM, Startseva E, le Roux CW et al. · Nature medicine · 2026
PMID 42252333 · DOI: 10.1038/s41591-026-04479-3
Preclinical research, reviews & other publications
Animal studies, laboratory experiments, reviews and other indexed papers answer different questions. A review is secondary evidence; a case report does not estimate how often an outcome occurs.
No additional matching publication was retained. The search links below allow further investigation; they are not evidence that a study exists.
Survodutide supplier sources
Scientific sources describe molecules and experiments. The commercial links below identify recorded supplier packages. A publication or chemical database entry does not verify the seller, purity, sterility or contents of a lot. Some links are affiliate links; see our disclosure.
Survodutide for sale: compare prices, sizes and forms from every tracked supplier →
| Supplier | Recorded packages | Example source listing |
|---|---|---|
| Amino USAUSD | 6mg Vial1 recorded offers | 6mg Vial · $90.00Checked Oct 13, 2026Supplier listing, Survodutide 6mg Vial, Amino USA, opens in a new tab |
| Cenexa LabsUSD | 10mg Vial1 recorded offers | 10mg Vial · $118.99Checked Oct 7, 2026Supplier listing, Survodutide 10mg Vial, Cenexa Labs, opens in a new tab |
Reference sources & further reading
- PubChem compound record 168429725 — chemical identity and structure.
- ChEMBL drug record CHEMBL5314776 — development stage, mechanism and synonyms.
- Wikipedia: Survodutide — Background encyclopedia; not a primary clinical source.
The citations above link directly to publication records. Encyclopedia links are background reading and are not used to establish clinical effectiveness.
Search for additional research
These links run searches; their results have not been individually reviewed and can include unrelated compounds.
Research information is not a dosing guide or a recommendation for personal use. Study findings are specific to the formulation, population and methods tested. Read our source and correction policy.
Related research profiles
Cagrilintide
C194H312N54O59S2
4409 g/mol · PubChem CID 171397054
5 selected publications · 4 human intervention studies · 40 registered trials
Protein / peptide · highest stage: Phase 3
Eloralintide
Molecular identity needs further verification
4 selected publications · 3 human intervention studies · 22 registered trials
Liraglutide
C172H265N43O51
3751 g/mol · PubChem CID 16134956
7 selected publications · 4 human intervention studies · 33 registered trials
US: active ingredient of an FDA-approved medicine · Drugs@FDA
Protein / peptide · highest stage: Approved in at least one jurisdiction (ChEMBL phase 4)
Mazdutide
C207H317N45O65
4476 g/mol · PubChem CID 167312357
7 selected publications · 6 human intervention studies · 40 registered trials
Protein / peptide · highest stage: Phase 3
Orforglipron Capsules
C48H48F2N10O5
883.0 g/mol · PubChem CID 137319706
8 selected publications · 6 human intervention studies · 40 registered trials
Small molecule · highest stage: Phase 3
Retatrutide
C221H342N46O68
4731 g/mol · PubChem CID 171390338
9 selected publications · 7 human intervention studies · 34 registered trials